Showing 8011-8020 of 10580 results for "".
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://practicaldermatology.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://practicaldermatology.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at
- Real-World Data Confirm Upadacitinib Effectiveness Across Body Regionshttps://practicaldermatology.com/news/real-world-data-confirm-upadacitinib-effectiveness-across-body-regions/2486450/Real-world evidence from the AD-VISE study demonstrates consistent and robust effectiveness of upadacitinib across body regions in patients with atopic dermatitis (AD), reinforcing outcomes observed in controlled clinical trials, according to data discussed by Melinda Gooderham, MD, MSc, at the A
- Envudeucitinib Outperforms Placebo and Apremilast in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-outperforms-placebo-and-apremilast-in-phase-3-psoriasis-trials/2486447/Envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated significant efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to Phase 3 data from the ONWARD 1 and ONWARD 2 trials presented by Andrew Blauvelt, MD, MBA,
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://practicaldermatology.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.